Aging, Geriatric Syndromes and Clonal Hematopoiesis

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Nov 12, 2015

Keywords

ClinConnect Summary

This clinical trial, titled "Aging, Geriatric Syndromes and Clonal Hematopoiesis," is studying the relationship between aging and various health conditions, particularly cardiovascular diseases. Researchers want to understand how certain health factors and mutations in the blood are related, regardless of a person's actual age. To do this, they will conduct a thorough health assessment that looks at multiple aspects of an older adult's life, including their overall health, medications, physical abilities, mental health, and social support. This approach recognizes that aging affects everyone differently.

If you are at least 50 years old, can read and understand English, and are willing to take part in the study, you may be eligible. However, some people may not qualify, such as those with certain recent illnesses or ongoing cancer treatments. Participants will complete health questionnaires and may undergo additional tests, like a bone marrow biopsy, if they choose. This study aims to gather valuable information about aging and health, which could lead to better care for older adults in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At least 50 years of age.
• • Able to understand written and spoken English.
• • Able to understand and willing to sign an IRB-approved written informed consent document (or that of a legally authorized representative, if applicable for the trauma cohort)
• Exclusion Criteria:
• • Inability or unwillingness to complete health questionnaire.
• • History of a recent (\<30 days) acute viral illness.
• • Current cancer diagnosis and currently receiving chemotherapy or undergoing radiation therapy. A prior history of cancer is allowed if the participant completed therapy \> 1 year prior to enrollment; participants with a prior diagnosis of cancer will be asked to sign a release of information for the research team to obtain records regarding their prior cancer treatment.
• • Current use of drugs that cause DNA damage (e.g. Cytoxan, azathioprine, etc.) for the treatment of a non-malignant disease.
• • Vulnerable populations (e.g. prisoners).
• • Known infection with Hepatitis B or C, HTLV, or HIV.
• * Additional exclusion for optional bone marrow aspirate/biopsy substudy:
• • Use of medications for anticoagulation or "blood thinning" including warfarin, low molecular weight heparins (enoxaparin, daltaparin) or direct-acting oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban or betrixaban)
• • allergy to lidocaine or other local anesthetics.